The news: A newly modified FDA order allows Philip Morris' ZYN nicotine pouches to be marketed as less harmful than cigarettes. The order allows marketing that says adults who switch from cigarettes to ZYN reduce their risk of some smoking-related diseases, making it the first nicotine pouch brand cleared for this type of claim.

Meanwhile, medical groups have raised concerns about nicotine pouches, including nicotine addiction and cardiovascular effects, as well as the long-term effects of prolonged contact with oral tissue.

Why it matters: The FDA authorization is narrowly limited to adults who specifically switch from cigarettes to ZYN, but that nuance could be lost as the message spreads on social media, where nicotine pouches are already popular among young consumers. The distinction between being less harmful than cigarettes and being safe may blur.

Nicotine pouch use among ages 21 and younger nearly quadrupled between 2022 and 2025, according to the CDC Foundation. ZYN dominates the category: 69% of middle and high school nicotine pouch users use ZYN, more than the next four brands combined, according to the FDA’s 2025 Youth Tobacco Survey.

The gap between less harmful and safe already is amplified through social media. While Philip Morris says it doesn't use ZYN influencers or accept partnership requests, an organic wave of "Zynfluencer" creators and celebrities, including podcaster Joe Rogan and Buffalo Bills quarterback Josh Allen, have promoted the brand online.

A recent analysis of the 100 most-viewed TikTok videos tagged #ZYN found 400 million combined views and 3.8 million shares. Yet just 5% portrayed ZYN as a smoking cessation tool and only 17% included any health warnings, while 79% took a positive tone, according to the Nicotine & Tobacco Research analysis published in February.

Implications for healthcare systems and providers: Many young people still see a pediatrician or primary care provider, but nicotine pouch use is unlikely to come up unprompted, especially with new claims beginning to circulate that may make it seem less risky. That makes proactive screening more important, such as adding nicotine pouch questions to routine intake for adolescents and teens, and discussing use during sports physicals or dental visits.

But given the volume of ZYN content already circulating on social media, in-office conversations alone may not be enough. Countering that narrative will likely require coordinated digital messaging from healthcare systems, public health organizations, and trusted clinicians on the same platforms where young people already engage with ZYN content.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.